Germany's Alzchem reports record 2025 sales, EBITDA on specialty chemicals boost

AlzChem AG

27/02/2026 06:11

Overview

Germany specialty chemicals firm says 2025 sales rose to EUR 562.1 mln, near its target

EBITDA increased 11% to EUR 116.5 mln, exceeding company forecast

Outlook

Alzchem forecasts 2026 sales around EUR 600 mln and EBITDA around EUR 126 mln

Company expects initial contributions from expanded capacities in 2026

Alzchem anticipates growth in Specialty Chemicals segment in 2026

Result Drivers

SPECIALTY CHEMICALS GROWTH - Specialty Chemicals segment saw an 8.8% sales increase, driven by demand for creatine products and nitroguanidine

CUSTOM MANUFACTURING IMPROVEMENT - Improved utilization of multi-purpose plants in Custom Manufacturing segment boosted performance

BASICS & INTERMEDIATES CHALLENGES - Segment faced a 10.9% sales decline due to weak demand from European steel industry and price competition

Company press release: ID:nEQ7f1pLBa

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
FY EBITDA
EUR 116.50 mln
FY Free Cash Flow
EUR 40.10 mln


Analyst Coverage

The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 7 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the specialty chemicals peer group is "buy."

Wall Street's median 12-month price target for Alzchem Group AG is €180.00, about 14.9% above its February 26 closing price of €156.60

The stock recently traded at 25 times the next 12-month earnings vs. a P/E of 25 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)